BETA - How are rural CAR-T cell therapy barriers being addressed?

In the fight against cancer, cutting edge treatments like CAR T cell therapy are transforming lives. But for patients in rural communities, accessing this life-saving innovation can feel like a world away. Long travel times, limited resources, and fewer specialists, these challenges create serious barriers. But the story doesn't end there. Across the country, healthcare innovators, policymakers, and communities are stepping up finding real solutions to bring CAR T therapy closer to home. In this Health Tree University lesson, we'll explore the strategies being explored to break down access barriers for rural patients. How are rural CAR T cell therapy barriers being addressed? I think that there are some challenges here that relate to what type of facilities are able to give CAR T. Can we help expand the number of institutions that can safely deliver CAR T therapy? Trying to add more centers to the list of those currently approved could certainly help address some of the access issues. If you have a maximizing the number of hospitals that serve rural areas, trying to help facilitate their care of rural patients. This might be transportation, this might be remote types of monitoring, new ways to leverage technology to ensure that the care is being delivered properly. All of these are potential ways that we could try to help extend the benefits of CAR T to those who live in more rural populations. For those centers who are currently delivering CAR T therapy, I think there could be greater investment in methods to help patients come from a distance, receive CAR T at their center. Potentially this could be facilitating staying in a local hotel, having a robust outpatient care program, having some help with patient navigation to help arrange the logistics of uprooting one's life, coming many hours away to go to a specialized center and trying to the length of time that was required to get the CAR T cells to be evaluated for them, to get the cells collected, to get the care you need to bridge you to when they're ready, which can sometimes span up to two to three months to get everything ready. And then to think about receiving the CAR T and the post-CAR T process, we're talking about several months of time. I think that for centers, and my center included, it would be great if we had more resources available to help with relocating patients and helping support them while they've been relocated closer to our center. The expansion of facilities that can give CAR T is, I think, a bigger question, a bigger problem. But I think as we get more experience as a community delivering CAR T and trying to minimize the side effects that require the expertise of a big academic center, that could probably also be a way we could help improve access to CAR T for patients who live in rural areas. I think it has to be a multifaceted approach. I think, for example, telemedicine helps in the sense that you could do some visits per year post-infusion utilizing telemedicine. I think that might be helpful. But also, generally from clinical trial to real-world practice, we can treat patients with kind of expanded eligibility in the sense that more patients might be able to get the treatment or be eligible for the treatment. But I really think the key to improving that access beyond the financial support and patient programs is going to be partnering with the community oncologists and kind of working together to manage some of these visits, some of the side effects that might arise from the immunotherapies. But nonetheless, I think we have a lot of work to do, whether it be in investing in infrastructure, patient navigation, and just different programs to help make this access a little bit easier for our patients with these novel therapies. Car T Therapy. Community outreach and engagement is very, very important. I think provider education, patient education, patient navigators, or care coordinators to help. Having these type of events like we're having today, like the round table patient advocacy groups, I think these are really all very important. I think at the heart of all of this is education, education, education, and super important to kind of have those, fostering those long-term relationships with the community providers, with the patients, and also having a culturally sensitive outreach approach and having, for example, multilingual information packets and education packets as well, I think could be some key factors. As I mentioned, lots of work to do, but I think this might be a good start. Is there support available to help cover lodging and transportation costs for patients who need to relocate for CAR T treatment? Yeah, so both CAR T companies, so both BMS and Janssen are providing patient support programs that generally will help with lodging and transportation. I think it's been actually very helpful. At times, let's say if we need bridging that might have to be done at the academic center, they also might help cover and support some of those costs. If you need to buy specific for a month, they might cover that or help support with that process until the CAR Ts are ready. I think they've tried to be helpful and there are support programs out there to assist with these type of needs. Is a full-time caregiver required to stay with the patient throughout the CAR T treatment process? So, unfortunately, yeah, that's one of the mandatory requirements is that you have to have a 24-hour caregiver. Because a lot of the time, for example, with CAR-VICTi, we're doing it all outpatient. So if somebody has a fever or if they have a neurologic complication, even worse, obviously we would want to make sure a caregiver is present to give us a call, bring the patient in or for any acute needs that might arise during that period. Are there programs to help patients without a caregiver find one for the CAR T process? Generally, at our center, we do require a known caregiver, generally like a family member or a friend or a neighbor or somebody that knows you and has a vested interest in you and your well-being. The problem with having hired help is that they might not be as committed, right? Maybe if things get tough, they might not be around or they might leave because they have something else going on. I think while that is an option, it's not a preferred option, generally we do prefer relatives or friends that are really committed to the patient and will help them through good times and bad times. To learn more about CAR T therapy, make sure you watch our course on CAR T treatment in our Immunotherapy T-Cell Redirecting Therapies module.